Esophageal squamous cell carcinoma (ESCC) has been generally considered as one of the most aggressive cancers with poor prognosis. Vimentin is the major protein constituent of intermediate filaments in normal and neoplastic mesenchymal cells, and has been regarded as a marker of epithelial-mesenchymal transition (EMT). However, little is known about ESCC with vimentin expression as a marker of EMT. In this study, we analyzed vimentin expression in 129 cases of ESCC in order to elucidate whether vimentin expression is correlated with clinicopathological features and aggressive behavior of ESCC. Vimentin expression was identified in 96 of the 129 cases (74.4%). The cases with vimentin-positive carcinoma cells showed a significantly higher incidence of lymph node metastasis (P = 0.001). Carcinomas with vimentin expression were more advanced in terms of tumor status and lymphatic invasion (P = 0.001, P = 0.009, respectively), and associated with stronger stromal α-smooth muscle actin (α-SMA) expression (P < 0.001). Vimentin expression was also associated with distant metastasis, including distant node metastasis (P = 0.014). Vimentin expression in both primary and metastatic carcinomas was found in 68.6% (48/70) of the cases, while no vimentin expression in both primary and metastatic carcinomas comprised 92.3% of the cases (12/13) (P < 0.001). In conclusion, we demonstrated that vimentin expression in ESCC is an independent predictor of lymph node metastasis (multivariate analysis, P = 0.014, odds ratio: 3.314, 95% confidence interval: 1.276-8.605). In addition, vimentin expression was frequently retained in metastatic carcinoma of the lymph node.
The occurrence of esophageal squamous cell carcinoma (ESCC) exhibits geographic and ethnic variation throughout the world. Iran, Central China, and South Africa have the highest incidence rates in the world (8) . In Japan, more than 90% of esophageal cancer is squamous cell carcinoma (9) , and the incidence of esophageal cancer is 20.0 per 100,000 population in males and 3.8 in females (17) . The mortality rate is 15.4 per 100,000 population in males and 2.7 in females (18) . Despite advances in surgical strategies and postoperative management, ESCC has been generally considered as one of the most aggressive cancers with poor prognosis (1, 19) . The reason for the poor survival rate is that most patients are present with an advanced stage of the disease, and with tumors metastasizing to the lymph nodes even in the early phase of wall penetration (11) . Lymph node metastasis is the most crucial parameter for predicting survival (16, 29, 35) . The spread of cancer cells via the lymphatic system to regional lymph nodes is an important early event INFc; and INFc, the tumor showing scirrhous growth and an indistinct border with the surrounding tissue (21) . In each patient, one representative histological specimen at the deepest invaded area of an esophageal cancer lesion was selected for immunohistochemistry. Four-micrometer-thick sections were mounted on silane-coated glass slides. Immunohistochemical examination was performed on deparaffinized sections using the standard avidin-biotinperoxidase complex (ABC) method with automated immunostainer (Benchmark XT; Ventana Medical System, Tucson, AZ, USA). The first antibodies used for immunohistochemistry were anti-vimentin (clone 3B4, mouse monoclonal, 1 : 50 dilation; Dakocytomation, Denmark) and anti-human smooth muscle actin (α-SMA, clone 1A4, mouse monoclonal, 1 : 200 dilation; Dakocytomation). Heat-induced antigen retrieval was performed for each antigen. In addition, in cases of lymph node metastasis, the largest metastatic carcinoma specimen was selected, and the same immunohistochemical examination of vimentin was performed.
Evaluation of immunohistochemistry.
Immunohistochemical expression of cytoplasmic vimentin was evaluated for the invasive region of tumors, and was classified into the following four groups: negative, focal, patchy, and diffuse. Immunohistochemical expression of α-SMA was evaluated for stromal cells around tumors (i.e. stromal α-SMA), and classified into the following four groups: none, no staining; mild, positive staining in single cells or sporadically occurring cell nests; moderate, positive staining in numerous cell complexes; and intense, positive staining in the majority of cells (6).
Statistical analysis.
Fisher's exact test was used to compare categorical variables among carcinomas with or without lymph node metastasis. An independent Student's t-test was used to compare ages. Multivariate regression analyses were performed by a logistic regression analysis to assess the odds ratio and 95% confidence interval of each variable for predicting lymph node metastasis. The P values were two-sided, and P values of < 0.05 were considered statistically significant. We used SPSS software, version 10.0 (SPSS, Inc., Chicago, IL, USA). during tumor progression, and lymph node metastasis is a key factor in the staging of human cancers (24, 27) . Despite the major role of the lymphatic system in the initial spread of cancers, little is known about the mechanisms involved (28) . Recent studies suggest that epithelial-mesenchymal transition (EMT) is related to lymph node metastasis in esophageal cancers (20, 34) . EMT, which is defined as the conversion of a polarized, epithelial phenotype to a highly motile fibroblastoid or mesenchymal phenotype, has emerged as a central process during embryonic development and chronic inflammation and fibrosis, as well as cancer progression (4, 10). The intermediate filaments are a major component of the cytoskeleton in mesenchymal cells. Vimentin is the major protein constituent of intermediate filaments in normal and neoplastic mesenchymal cells, and is frequently used in the diagnosis of mesenchymal lesions (2, 5, 22). Vimentin has been regarded as a marker of EMT (7, 15), but little is known about ESCC with vimentin expression as a localized pathologic factor. In this study, we analyzed vimentin expression in 129 cases of ESCC in order to elucidate whether vimentin expression is correlated with clinicopathological features and aggressive behavior of ESCC.
MATERIALS AND METHODS

Patient materials.
One hundred and twenty-nine ESCC were surgically resected at Hirosaki University Hospital from 1996 to 2008. Informed consent was obtained from all the patients to use their clinical records and undertake pathological study. All the patients underwent operations including subtotal esophagectomy and dissection of lymph nodes. No patients received radiotherapy or chemotherapy before operation.
Histopathological and immunohistochemical examinations. Esophageal cancer specimens were routinely fixed with formalin, embedded in paraffin, thinsectioned, and stained with hematoxylin and eosin (H&E). The pathological stage of each case at the time of operation was defined according to the TNM classification (25) , and each lesion was graded his- were closely associated with the surrounding stromal cells expressing α-SMA. In addition, vimentin expression of metastatic carcinoma was identified in lymph nodes, as shown in Fig. 2 . Vimentin expression was found in the cytoplasm of the metastatic carcinoma, mainly in the invasive front, the same as that in primary carcinomas.
Clinicopathologic findings
Univariate analysis between lymph node metastasis and clinicopathological factors, including vimentin ing distant lymph node metastasis (P = 0.014). In the cases with lymph node metastasis (83 cases), vimentin expression in primary tumors and lymph nodal metastatic tumors was summarized in Table 3 . In the cases with vimentin expression in primary tumor (70 cases), vimentin expression in lymph nodal metastatic tumors was exhibited in 48 cases (68.6%). On the other hand, in the cases without vimentin expression in primary tumor (13 cases), no vimentin expression in lymph nodal metastatic tumors was exhibited in 12 cases (92.3%) (P < 0.001). Finally, we present the results of the multivariate analysis for lymph node metastasis (Table 4) . Vimentin expression was significantly associated with lymph node metastasis (P = 0.014, odds ratio: 3.314, 95% confidence interval: 1.276-8.605), while the associations of tumor status, lymphatic invasion and stromal α-SMA were not significant (P = 0.383, P = 0.082, P = 0.672, respectively). On the basis of these results, vimentin expression in the carcinoma cells, but not stromal α-SMA, is identified an independent predictor of lymph node metastasis.
RESULTS
Histological expression of vimentin and α-SMA
expression and α-SMA expression, is summarized in Table 1 . The mean age at the time of diagnosis was 65.3 years (range 37-83 years), and the sample group consisted of 115 men and 14 women. The gender and mean age did not differ significantly between the groups (P = 1.000, P = 0.855, respectively). Lymph node metastasis was found in 83 of the 129 cases (64.3%). Carcinomas with lymph node metastasis were more advanced in terms of tumor status and lymphatic invasion (P = 0.017, P = 0.017, respectively). The cases with vimentin-positive carcinoma cells and α-SMA-positive stromal cells showed a significantly higher incidence of lymph node metastasis (P = 0.001, P = 0.030, respectively). Next, we focused on the results for vimentin expression in primary tumors, which is summarized in Table 2 . Vimentin expression was identified in 96 of the 129 cases (74.4%). Carcinomas with vimentin expression were more advanced in terms of tumor status and lymphatic invasion (P = 0.001, P = 0.009, respectively), and associated with stronger stromal α-SMA expression (P < 0.001). Vimentin expression was also associated with distant metastasis, includ- 
DISCUSSION
Recently, vimentin has been regarded as a marker of EMT (7, 15). However, the expression and function of vimentin in the carcinoma cells have not yet been clarified in ESCC. In this study, we showed that vimentin expression was an independent predictor of lymph node metastasis in ESCC and was associated with lymphatic invasion, stromal α-SMA, and distant metastasis. In addition, vimentin expression was frequently preserved in metastatic carcinoma of the lymph node. EMT, which is defined as the conversion of a polarized, epithelial phenotype to a highly motile fibroblastoid or mesenchymal phenotype, has emerged as a central process during embryonic development and chronic inflammation and fibrosis, as well as cancer progression (4, 10). Recent research showed that some transcription factors induce EMT and are related to tumor status, lymph node metastasis and distant metastasis (20, 33, 34, 36) . In ESCC, lymph node metastasis is the most crucial parameter for predicting survival (16, 29, 35) . Therefore, it is indicated that EMT is significantly related to cancer prognosis. In addition, EMT is related to the prognosis of several other cancers, e.g. gastric cancer, pancreatic cancer, breast cancer, and non-small cell carcinoma of the lung (7, 12, 13, 26). Vimentin is the major protein constituent of intermediate filaments in normal and neoplastic mesenchymal cells and is frequently used for the diagnosis of mesenchymal lesions (2, 5, 22). For cancer EMT, the status of the intermediate filaments in a cell changes from a keratin-rich network, which connects to adherens junctions and hemidesmosomes, to a vimentin-rich network connecting to focal adhesions (7). Vimentin has been regarded as a marker of EMT and is related to poor prognosis (7, 15). Vimentin-positive carcinoma cells were found to have the following histological and immunohisto- progression (6). It is indicated that myofibroblastinduced tumor-stromal interaction resulted in a stromal microenvironment in which vimentin-positive carcinoma cells could easily invade lymphatic vessels. Thus, vimentin-positive carcinoma cells could easily invade the lymphatic vessels, which resulted in lymph node metastasis (Fig. 3) . ESCC has been generally considered as one of the most aggressive cancers with poor prognosis (1, 19) . The reason for the poor survival rate is that most patients are present with an advanced stage of the disease, and with tumors metastasizing to the lymph nodes even in the early phase of wall penetration (11) . Lymph node metastasis is the most crucial parameter of ESCC for predicting survival (16, 29, 35) . During the colonization in distant sites, a reverse of the process of mesenchymal-epithelial transition (MET) takes place and metastatic carcinoma cells again acquire the epithelial phenotype (31) . Our data showed that metastatic carcinoma cells retained vimentin expression even if carcinoma cells acquired the epithelial phenotype via MET.
In conclusion, we demonstrated that vimentin expression in ESCC is an independent predictor of lymph node metastasis. Therefore, this feature could be a significant histologic prognosis factor. In addition, vimentin expression was frequently retained in metastatic carcinoma of the lymph node. REFERENCE chemical characteristics: (1) they were detected in the carcinoma tissue, usually at a frequency of less than 10%, and were present at the invasive front of the carcinoma tissue; (2) they often showed spindle to polygonal shapes; and (3) they were closely associated with stromal α-SMA. Our statistical analysis showed that vimentin expression was significantly related to lymphatic invasion, stromal α-SMA, lymph node metastasis, and distant metastasis. Vimentin-positive carcinoma cells often formed small nests and were accompanied by desmoplastic change with α-SMA expression. Lymphatic vessels consist of a single layer of lymphatic endothelial cells, which are not surrounded by pericytes, smooth muscle cells or a regular basement membrane (32) . Owing these structures, the invasion of the small nest-shaped carcinoma cells into the lymphatic vessels might be facilitated, because of the higher permeability of the lymphatic vessels. Several studies have documented that tumor budding, which showed small nest-shaped structures, is significantly related to ESCC prognosis (14, 23) . However, vimentin expression in the carcinoma cells was not determined in these studies. α-SMA is a well-known marker of myofibroblast activation occurring in areas of tumor-stromal interaction (3). Myofibroblasts play an important role in the desmoplastic reaction as a dynamic stromal change occurring during tumor 
